Is Biogen Becoming A Reasonable Target For Acquisition? Baird Says So By: Benzinga via Benzinga June 22, 2016 at 15:21 PM EDT Baird's Brian Skorney reiterated Biogen Inc (NASDAQ: BIIB)'s Neutral rating with a $268 price target. The reiteration came after ... Read More >> Related Stocks: Biogen Idec Eisai Ltd ADR